Skip to main content
Smart Investors Daily
CD

NASDAQ · CDXC

ChromaDex Corporation

Healthcare · Biotechnology

$7.87

Down-$0.07 (-0.88%)

Updated Sep 17, 2026, 2:51 AM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
611.9M
P/E ratio
29.68
Dividend yield
0.00%
52-week range
$2.02 – $9.18
Volume
554.83K
Avg. volume
809.37K

Price performance

CDXC price history

1M range · 0 trading sessions · Daily adjusted prices

CDXC does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CDXC news

The latest Smart Investors Daily articles mentioning CDXC.

CDXC research

Overview

Company profile and research snapshot.

Company profile

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
CDXC recent ratings
DateFirmRatingTarget
Mar 17, 2025HC Wainwright & Co.Buy
Mar 10, 2025HC Wainwright & Co.Buy
Mar 5, 2025Ladenburg ThalmannBuy
Nov 6, 2024Roth MKMBuy
Nov 4, 2024HC Wainwright & Co.Buy
Open full forecast

News briefing

No generated briefing is available yet.

Zacks Investment Research · May 10, 2023

ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 40% and 16.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.